Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Discovering new MAP kinase inhibitors.

Paul Shapiro1

  • 1Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Room 536, 20 North Pine Street, Baltimore, MD 21201, USA.

Chemistry & Biology
|August 26, 2006
PubMed
Summary

Researchers identified a specific inhibitor for Spc1 MAP kinase in yeast. This molecule blocks protein interactions with Spc1, offering a new tool for studying this important signaling pathway.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication.

Journal of virology·2025
Same author

First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties.

The Journal of pharmacology and experimental therapeutics·2025
Same author

First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-stabilizing Properties.

The Journal of pharmacology and experimental therapeutics·2024
Same author

Integration of Hydrogen-Deuterium Exchange Mass Spectrometry with Molecular Dynamics Simulations and Ensemble Reweighting Enables High Resolution Protein-Ligand Modeling.

Journal of the American Society for Mass Spectrometry·2024
Same author

Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases.

Advances in pharmacology (San Diego, Calif.)·2024
Same author

Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors.

Bioorganic & medicinal chemistry·2024

Area of Science:

  • Molecular Biology
  • Yeast Genetics
  • Signal Transduction

Background:

  • Mitogen-activated protein (MAP) kinases are crucial in cellular signaling pathways.
  • Spc1 MAP kinase in the fission yeast Schizosaccharomyces pombe regulates stress responses.
  • Understanding Spc1 regulation is key to deciphering cellular stress mechanisms.

Purpose of the Study:

  • To identify novel, highly specific inhibitors of Spc1 MAP kinase.
  • To characterize the mechanism of inhibition for potential therapeutic or research applications.

Main Methods:

  • Utilized a genetic screening approach in Schizosaccharomyces pombe.
  • Investigated inhibitor interaction with Spc1 MAP kinase, focusing on substrate binding versus ATP binding.

Main Results:

  • Identified a novel inhibitor with high specificity for Spc1 MAP kinase.
  • The inhibitor was found to compete with protein substrates for Spc1 interaction sites.
  • Crucially, the inhibitor does not interfere with ATP binding to Spc1.

Conclusions:

  • A specific inhibitor of Spc1 MAP kinase has been discovered using a yeast model.
  • This inhibitor provides a valuable chemical probe for dissecting Spc1-mediated signaling pathways.
  • The findings open avenues for further research into kinase inhibitor development.

Related Experiment Videos